Free tool
FAERS Monitor: Mavyret
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209394 or its brand name (Mavyret, Glecaprevir, Pibrentasvir). Reports on generic versions are filed under their own applications.
Reports
10,976
Serious
2,823
26% of reports
Hospitalization
1,325
Death reported
296
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,568
- headache2,208
- nausea1,135
- pruritus662
- diarrhoea481
- vomiting317
- rash314
- dizziness232
- death231
- pain211
- insomnia201
- abdominal discomfort199
- drug ineffective193
- asthenia158
- abdominal pain upper149
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 156 |
| 2018 | 3,515 |
| 2019 | 3,713 |
| 2020 | 1,203 |
| 2021 | 526 |
| 2022 | 715 |
| 2023 | 437 |
| 2024 | 282 |
| 2025 | 266 |
| 2026 | 163 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,183 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| headacheSignal | 2,208 | 6.8 | 6.5 | 11,144 |
| fatigueSignal | 2,568 | 6.3 | 6.1 | 11,945 |
| pruritusSignal | 662 | 3.3 | 3.1 | 1,080 |
| nauseaSignal | 1,135 | 2.8 | 2.6 | 1,310 |
| abdominal discomfortSignal | 199 | 2.3 | 2.0 | 142 |
| insomnia | 201 | 1.4 | 1.3 | 28 |
| diarrhoea | 481 | 1.4 | 1.3 | 63 |
| abdominal pain upper | 149 | 1.4 | 1.2 | 16 |
| rash | 314 | 1.4 | 1.2 | 33 |
| vomiting | 317 | 1.3 | 1.2 | 21 |
| dizziness | 232 | 0.9 | 0.8 | 3 |
| asthenia | 158 | 0.8 | 0.7 | 7 |
| pain | 211 | 0.7 | 0.6 | 38 |
| death | 231 | 0.5 | 0.5 | 110 |
| drug ineffective | 193 | 0.3 | 0.2 | 379 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.